Search Results - "Briscoe, Karen"

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer by Lin, Hui-Ming, Mahon, Kate L, Spielman, Calan, Gurney, Howard, Mallesara, Girish, Stockler, Martin R, Bastick, Patricia, Briscoe, Karen, Marx, Gavin, Swarbrick, Alexander, Horvath, Lisa G

“…Background: Biomarkers of therapeutic response and prognosis are needed to assist in the sequencing of treatments for metastatic castration-resistant prostate…”
Get full text

Immunotherapy-related gastritis: Two case reports and literature review by Woodford, Rachel, Briscoe, Karen, Tustin, Richard, Jain, Ankit

“…Immunotherapy is increasingly defining a role in a wide variety of tumours such that as use becomes more ubiquitous, so too will the complications. A…”
Get full text

Development of clinically meaningful quality indicators for contemporary lung cancer care, and piloting and evaluation in a retrospective cohort; experiences of the Embedding Research (and Evidence) in Cancer Healthcare (EnRICH) Program by Brown, Bea, Galpin, Kirsty, Simes, John, Boyer, Michael, Brown, Chris, Chin, Venessa, Young, Jane, O’Donnell, Amy, Brown, Bea, McCaughan, Brian, Barnes, David, Seah, Davinia, McPhail, Diane, Young, Jane, Simes, John, Briscoe, Karen, Galpin, Kirsty, Boyer, Michael, Jones, Ruth, Chin, Venessa, Cooper, Wendy

“…ObjectivesLung cancer continues to be the most common cause of cancer-related death and the leading cause of morbidity and burden of disease across Australia…”
Get full text

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer by Mak, Blossom, Lin, Hui-Ming, Kwan, Edmond M, Fettke, Heidi, Tran, Ben, Davis, Ian D, Mahon, Kate, Stockler, Martin R, Briscoe, Karen, Marx, Gavin, Zhang, Alison, Crumbaker, Megan, Tan, Winston, Huynh, Kevin, Meikle, Thomas G, Mellett, Natalie A, Hoy, Andrew J, Du, Pan, Yu, Jianjun, Jia, Shidong, Joshua, Anthony M, Waugh, David J, Butler, Lisa M, Kohli, Manish, Meikle, Peter J, Azad, Arun A, Horvath, Lisa G

“…Both changes in circulating lipids represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumour genetic aberrations are individually…”
Get full text

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG) by Siu, Ho Wai Derrick, Tebbutt, Niall, Chantrill, Lorraine, Karapetis, Chris, Steer, Christopher, Wilson, Kate, Espinoza, David, Bailey, Lisa, Yip, Sonia, Cuff, Jeff, Pavlakis, Nick, Thavaneswaran, Subotheni, Briscoe, Karen, Srivastav, Ratnesh, Shannon, Jennifer, Segelov, Eva, Tie, Jeannie, Caird, Susan, Francesconi, Alessandra, Price, Timothy, Wuttke, Melanie, Ladwa, Rahul, Sjoquist, Katrin, Burge, Matthew

“…Abstract Background Doublet chemotherapy in combination with a biologic agent has been a standard of care in patients with metastatic colorectal cancer for…”
Get full text

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase by Lin, Hui-Ming, Mak, Blossom, Yeung, Nicole, Huynh, Kevin, Meikle, Thomas G., Mellett, Natalie A., Kwan, Edmond M., Fettke, Heidi, Tran, Ben, Davis, Ian D., Mahon, Kate L., Zhang, Alison, Stockler, Martin R., Briscoe, Karen, Marx, Gavin, Crumbaker, Megan, Stricker, Phillip D., Du, Pan, Yu, Jianjun, Jia, Shidong, Scheinberg, Tahlia, Fitzpatrick, Michael, Bonnitcha, Paul, Sullivan, David R., Joshua, Anthony M., Azad, Arun A., Butler, Lisa M., Meikle, Peter J., Horvath, Lisa G.

“…Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 20–30% of men with metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma by Nayar, Namrata, Briscoe, Karen, Fernandez Penas, Pablo

“…Nivolumab is a fully humanized monoclonal antibody to PD-1, which has shown improved overall and progression-free survival. Across studies of nivolumab, grade…”
Get full text

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in by Nowak, Anna K, Lesterhuis, W Joost, Kok, Peey-Sei, Brown, Chris, Hughes, Brett GM, Karikios, Deme J, John, Thomas, Kao, Steven C-H, Leslie, Connull, Cook, Alistair M, Pavlakis, Nick, Briscoe, Karen, O'Byrne, Kenneth J, Karapetis, Christos S, Lam, Wei-Sen, Langford, Ailsa, Yip, Sonia, Stockler, Martin R

“…There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural…”
Get full text

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial by Sweeney, Christopher J, Martin, Andrew J, Stockler, Martin R, Cheung, Leanna, Chi, Kim N, Chowdhury, Simon, Frydenberg, Mark, Joshua, Anthony M, Lawrence, Nicola J, Marx, Gavin, McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A, Parnis, Francis, Parulekar, Wendy, Pook, David W, Reaume, Martin Neil, Sandhu, Shahneen K, Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Vera-Badillo, Francisco, Williams, Scott G, Yip, Sonia, Zielinski, Robert R, Davis, Ian D, Abdi, Ehtesham, Bastick, Patricia, Begbie, Stephen, Blum, Robert, Briscoe, Karen, Brungs, Daniel, Bydder, Sean, Chittajallu, Bala Renuka, Cronk, Michelle, Cuff, Katharine, Davis, Ian D, Dowling, Anthony, Frydenberg, Mark, Horvath, Lisa, Hovey, Elizabeth, Joshua, Anthony, Karanth, Narayan, Kichenadasse, Ganessan, Krieger, Laurence, Marx, Gavin, Mathlum, Maitham, Nott, Louise, Otty, Zulfiquer, Parnis, Francis, Pook, David, Sandhu, Shahneen, Sewak, Sanjeev, Stevanovic, Amanda, Suder, Aneta, Tan, Hsiang, Torres, Javier, Troon, Simon, Underhill, Craig, Weickhardt, Andrew, Zielinski, Robert, Anan, Ghadeer, Booth, Chris, Campbell, Holly, Chi, Kim, Chin, Joseph, Chouinard, Edmond, Drachenberg, Darrel, Faghih, Amir, Finelli, Antonio, Hotte, Sebastien, North, Scott, Rassouli, Mohammad, Reaume, Neil, Rendon, Ricardo, Saad, Fred, Sadikov, Evgeny, Vigneault, Eric, Zalewski, Pawel, McCaffrey, John, McDermott, Ray, Morris, Patrick, O'Connor, Miriam, Donnellan, Paul, Edwards, Jim, Fong, Peter, Tan, Alvin, Chowdhury, Simon, Crabb, Simon, Khan, Omar, Khoo, Vincent, Macdonald, Graham, Payne, Heather, Robinson, Angus, Shamash, Jonathon, Staffurth, John, Thomas, Carys, Thomson, Alastair, Sweeney, Christopher J

“…The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early…”
Get full text

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial by Friedlander, Michael, Mileshkin, Linda, Lombard, Janine, Frentzas, Sophia, Gao, Bo, Wilson, Michelle, Meniawy, Tarek, Baron-Hay, Sally, Briscoe, Karen, McCarthy, Nicole, Fountzilas, Christos, Cervantes, Andres, Ge, Ruimin, Wu, John, Spira, Alexander

“…Background The aim of this study was to investigate the antitumour activity, safety, and tolerability of pamiparib plus tislelizumab in patients with…”
Get full text

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials by Long, Georgina V, Weber, Jeffrey S, Larkin, James, Atkinson, Victoria, Grob, Jean-Jacques, Schadendorf, Dirk, Dummer, Reinhard, Robert, Caroline, Márquez-Rodas, Ivan, McNeil, Catriona, Schmidt, Henrik, Briscoe, Karen, Baurain, Jean-François, Hodi, F Stephen, Wolchok, Jedd D

“…Immune checkpoint inhibitors have demonstrated atypical response patterns, which may not be fully captured by conventional response criteria. There is a need…”
Get more information

A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer by Lin, Hui‐Ming, Mahon, Kate L., Weir, Jacquelyn M., Mundra, Piyushkumar A., Spielman, Calan, Briscoe, Karen, Gurney, Howard, Mallesara, Girish, Marx, Gavin, Stockler, Martin R., PRIMe Consortium, Parton, Robert G., Hoy, Andrew J., Daly, Roger J., Meikle, Peter J., Horvath, Lisa G.

“…Lipids are known to influence tumour growth, inflammation and chemoresistance. However, the association of circulating lipids with the clinical outcome of…”
Get full text

Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study by McLean, Luke S, Lim, Annette M, Bressel, Mathias, Lee, Jenny, Ladwa, Rahul, Guminski, Alexander D, Hughes, Brett, Bowyer, Samantha, Briscoe, Karen, Harris, Samuel, Kukard, Craig, Zielinski, Rob, Alamgeer, Muhammad, Carlino, Matteo, Mo, Jeremy, Park, John J, Khattak, Muhammad A, Day, Fiona, Rischin, Danny

“…Objectives To review the outcomes of immune checkpoint inhibitor (ICI) treatment of advanced cutaneous squamous cell carcinoma (CSCC) outside clinical trials…”
Get full text

Efficacy of programmed cell death protein 1 (PD1) inhibitors in cutaneous squamous cell carcinoma (cSCC) patients with large nerve-perineural invasion (LN-PNI): A multicenter retrospective study by Shrestha, Prajwol, Ladwa, Rahul, Heller, Gillian, Low, Tsu-Hui (Hubert), Palme, Carsten, Shannon, Kerwin Frank, Briscoe, Karen P., Hayat, Faisal, Clark, Jonathan, Gupta, Ruta, Hughes, Brett Gordon Maxwell, Lee, Jenny HJ

“…e21577 Background: Response rates to PD1 inhibitors are high in unresectable locally advanced or metastatic cSCC. However, the management of cSCC patients with…”
Get full text

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 by Dummer, Reinhard, Corrie, Pippa, Gutzmer, Ralf, Meniawy, Tarek M, Del Vecchio, Michele, Lebbé, Céleste, Guida, Michele, Dutriaux, Caroline, Dreno, Brigitte, Meyer, Nicolas, Ferrucci, Pier Francesco, Dalle, Stéphane, Khattak, Muhammad Adnan, Grob, Jean-Jacques, Briscoe, Karen, Larkin, James, Mansard, Sandrine, Lesimple, Thierry, Guidoboni, Massimo, Sabatini, Silvia, Richtig, Erika, Herbst, Rudolf, Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A, Maio, Michele

“…To address the paucity of data in patients with historically poor outcomes, we conducted the single-arm phase IIIb CheckMate 401 study to evaluate the safety…”
Get full text

Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial by Mersiades, Antony, Kirby, Adrienne, Stockler, Martin R., Tognela, Annette, Olver, Ian N., Morton, Rachael L., Haber, Paul, Walsh, Anna, Lee, Yvonne, Abdi, Ehtesham A., Della-Fiorentina, Stephen, Aghmesheh, Morteza, Fox, Peter, Briscoe, Karen P., Sanmugarajah, Jasotha, Marx, Gavin M., Kichenadasse, Ganessan, Wheeler, Helen, Simes, John, Grimison, Peter S.

“…12019 Background: The aim of this multi-centre, randomised, placebo-controlled, phase II/III trial was to determine the efficacy of adding an oral THC/CBD…”
Get full text

Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer by Mahon, Kate L., Sutherland, Sarah IM, Lin, Hui Ming, Stockler, Martin R., Gurney, Howard, Mallesara, Girish, Briscoe, Karen, Marx, Gavin, Higano, Celestia S., Bono, Johann S., Chi, Kim N., Clark, Georgina, Breit, Samuel N., Brown, David A., Horvath, Lisa G.

“…Background Elevated circulating growth differentiation factor (GDF15/MIC‐1), interleukin 4 (IL4), and IL6 levels were associated with resistance to docetaxel…”
Get full text

A case of cutaneous metastasis of the scalp from colorectal adenocarcinoma by Tran, Michael, Lea, Vivienne, Briscoe, Karen

Get full text

Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer by Mahon, Kate Lynette, Lin, Hui-Ming, Lee-Ng, Michelle, Stockler, Martin R., Gurney, Howard, Mallesara, Girish, Briscoe, Karen P., Marx, Gavin M., Higano, Celestia S., De Bono, Johann S., Chi, Kim N., Brown, David, Breit, Samuel N., Horvath, Lisa

“…Abstract only 230 Background: Elevated circulating macrophage inhibitory cytokine -1 /growth differentiation factor 15 (MIC-1/GDF15), interleukins 4 (IL4) and…”
Get full text

Results of crossover phase II component of randomized placebo-controlled trial evaluating oral THC/cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV) by Grimison, Peter S., Stockler, Martin R., Kirby, Adrienne, Walsh, Anna, Lintzeris, Nicholas, Cheung, Yvonne, Mersiades, Antony, Tognela, Annette, Haber, Paul, Simes, John, Morton, Rachael L., Olver, Ian N., McGregor, Iain, Gedye, Craig, Fox, Peter, Briscoe, Karen P., Aghmesheh, Morteza, Abdi, Ehtesham A., Clarke, Stephen John, Della-Fiorentina, Stephen

“…Abstract only 12008 Background: The aim of this multi-centre, randomised, double-blinded, placebo-controlled, phase 2/3 trial is to determine efficacy of…”
Get full text